Paper40686644
Peptide-based therapeutic and delivery strategies for inflammatory bowel disease: challenges and future directions.
Ge C and 3 others. RSC Adv, 2025. Cited by 8 papers, by iCite.
Cite this record
ConductScience Library. Peptide-based therapeutic and delivery strategies for inflammatory bowel disease: challenges and future directions. Papers, record 40686644. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40686644
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Peptide-based therapeutic and delivery strategies for inflammatory bowel disease: challenges and future directions.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References155
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 39746581 | Dihydromyricetin/montmorillonite intercalation compounds ameliorates DSS-induced colitis: Role of intestinal epithelial barrier, NLRP3 inflammasome pathway and gut microbiota. | Int J Pharm | 2025 | https://conductscience.org/library/papers/39746581 | PubMed |
| 2 | 38638365 | Development of Ac2-26 Mesoporous Microparticle System as a Potential Therapeutic Agent for Inflammatory Bowel Diseases. | Int J Nanomedicine | 2024 | https://conductscience.org/library/papers/38638365 | PubMed |
| 3 | 25371141 | Antimicrobial peptides: therapeutic potentials. | Expert Rev Anti Infect Ther | 2014 | https://conductscience.org/library/papers/25371141 | PubMed |
| 4 | 32768972 | Site-specific targeted drug delivery systems for the treatment of inflammatory bowel disease. | Biomed Pharmacother | 2020 | https://conductscience.org/library/papers/32768972 | PubMed |
| 5 | 34713621 | Polydopamine Nanoparticle-Mediated Dopaminergic Immunoregulation in Colitis. | Adv Sci (Weinh) | 2022 | https://conductscience.org/library/papers/34713621 | PubMed |
| 6 | 32714090 | Anti-Inflammatory Effect of a Peptide Derived from the Synbiotics, Fermented Cudrania tricuspidata with Lactobacillus gasseri, on Inflammatory Bowel Disease. | Mediators Inflamm | 2020 | https://conductscience.org/library/papers/32714090 | PubMed |
| 7 | 39587209 | Orally delivered biodegradable targeted inflammation resolving pectin-coated nanoparticles induce anastomotic healing post intestinal surgery. | Sci Rep | 2024 | https://conductscience.org/library/papers/39587209 | PubMed |
| 8 | 33803138 | Antioxidant Therapy in Inflammatory Bowel Diseases. | Antioxidants (Basel) | 2021 | https://conductscience.org/library/papers/33803138 | PubMed |
| 9 | 39569007 | Sturgeon-derived peptide LLLE alleviates colitis via regulating gut microbiota and its metabolites. | Curr Res Food Sci | 2024 | https://conductscience.org/library/papers/39569007 | PubMed |
| 10 | 34399466 | Recent developments on production, purification and biological activity of marine peptides. | Food Res Int | 2021 | https://conductscience.org/library/papers/34399466 | PubMed |
| 11 | 35780549 | Orally administered covalently-assembled antioxidative peptide nanoparticles for inflammatory bowel disease therapy. | J Colloid Interface Sci | 2022 | https://conductscience.org/library/papers/35780549 | PubMed |
| 12 | 31157495 | Efficient Phage Display with Multiple Distinct Non-Canonical Amino Acids Using Orthogonal Ribosome-Mediated Genetic Code Expansion. | Angew Chem Int Ed Engl | 2019 | https://conductscience.org/library/papers/31157495 | PubMed |
| 13 | 32097742 | Chitosan-based hydrogel beads: Preparations, modifications and applications in food and agriculture sectors - A review. | Int J Biol Macromol | 2020 | https://conductscience.org/library/papers/32097742 | PubMed |
| 14 | 39321686 | Targeted V-type peptide-decorated nanoparticles prevent colitis by inhibiting endosomal TLR signaling and modulating intestinal macrophage polarization. | Biomaterials | 2025 | https://conductscience.org/library/papers/39321686 | PubMed |
| 15 | 37859689 | A nanoparticle platform for combined mucosal healing and immunomodulation in inflammatory bowel disease treatment. | Bioact Mater | 2024 | https://conductscience.org/library/papers/37859689 | PubMed |
| 16 | 39554349 | Structure and regulatory mechanisms of food-derived peptides in inflammatory bowel disease: A review. | Food Sci Nutr | 2024 | https://conductscience.org/library/papers/39554349 | PubMed |
| 17 | 35415304 | Sprayable nanomicelle hydrogels and inflammatory bowel disease patient cell chips for development of intestinal lesion-specific therapy. | Bioact Mater | 2022 | https://conductscience.org/library/papers/35415304 | PubMed |
| 18 | 23428883 | Approaches for enhancing oral bioavailability of peptides and proteins. | Int J Pharm | 2013 | https://conductscience.org/library/papers/23428883 | PubMed |
| 19 | 18602004 | Peptide-mediated interactions in biological systems: new discoveries and applications. | Curr Opin Biotechnol | 2008 | https://conductscience.org/library/papers/18602004 | PubMed |
| 20 | 34887639 | Antimicrobial peptides and the gut microbiome in inflammatory bowel disease. | World J Gastroenterol | 2021 | https://conductscience.org/library/papers/34887639 | PubMed |
Cited by8
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42941186 | Inflammatory Bowel Disease: From Multifactorial and Metabolic Pathogenesis to Systemic Disease and Precision Medicine. | Metabolites | 2026 | https://conductscience.org/library/papers/42941186 | PubMed |
| 42898959 | Targeting pathogenic immune cells in rheumatoid arthritis: emerging immunotherapeutic frontiers. | Front Immunol | 2026 | https://conductscience.org/library/papers/42898959 | PubMed |
| 42796959 | Adzuki Bean Peptide Prevents DSS-Induced Colitis by Modulating the Gut Microbiota. | Nutrients | 2026 | https://conductscience.org/library/papers/42796959 | PubMed |
| 42388373 | Oral hydrogel systems in lower gastrointestinal disorders: From disease-based therapy to microbiota-guided design. | Mater Today Bio | 2026 | https://conductscience.org/library/papers/42388373 | PubMed |
| 42196602 | Mechanistic Insights into Dihydromyricetin: Redox Modulation and Kinase-Mediated Control of Disease Pathogenesis. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42196602 | PubMed |
| 42126606 | Cytokine and chemokine dysregulation by microbial biofilm components: mechanisms and clinical implications. | Arch Microbiol | 2026 | https://conductscience.org/library/papers/42126606 | PubMed |
| 42079437 | Decoy Nanoparticles and Protein Corona Modulation: A Novel Frontier in Sepsis Treatment. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/42079437 | PubMed |
| 41278154 | Research progress concerning the involvement of the intestinal microbiota in the occurrence and development of inflammatory bowel disease. | World J Gastroenterol | 2025 | https://conductscience.org/library/papers/41278154 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40686644
GET https://conductscience.org/api/papers/v1/40686644/references?page=2